Evidence map›Paper›PMID 28432529›Full record

ArticleChinese journal of integrative medicine2018

Ginseng-Derived Panaxadiol Saponins Promote Hematopoiesis Recovery in Cyclophosphamide-Induced Myelosuppressive Mice: Potential Novel Treatment of Chemotherapy-Induced Cytopenias.

Xin Sun, Yan-Na Zhao, Song Qian, Rui-Lan Gao, Li-Ming Yin, Li-Pei Wang, Beng-Hock Chong, Su-Zhan Zhang

Abstract read
PubMed Publisher
In one paragraph

Article in Chinese journal of integrative medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
0.9field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 27 citations in OpenAlex.

  1. The Journal of international medical research · 2020
    Trial
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Traditional Chinese medicine for treating aplastic anemia.Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques · 2023
    Review
  8. Pharmaceuticals (Basel, Switzerland) · 2022
    Article
  9. Article
  10. Article
  11. Journal of ginseng research · 2021
    Review
  12. Article
  13. TMEA, a Polyphenol inFrontiers in cell and developmental biology · 2021
    Article
  14. Article
  15. Article
  16. Article
  17. Compatibility effects of ginseng andJournal of ginseng research · 2020
    Article
  18. Article
  19. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 2 countries.

Xin SunDepartment of Oncology, The Second Affiliated Hospital, Medical College of Zhejiang University, Hangzhou, 310009, China.
Yan-Na ZhaoInstitution of Hematology Research, The First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, 310006, China.
Song QianInstitution of Hematology Research, The First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, 310006, China.
Rui-Lan GaoInstitution of Hematology Research, The First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, 310006, China.
Li-Ming YinInstitution of Hematology Research, The First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, 310006, China.
Li-Pei WangInstitution of Hematology Research, The First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, 310006, China.
Beng-Hock ChongDepartment of Hematology, St George Sutherland Hospital, Sydney, NSW, 2217, Australia.
Su-Zhan ZhangDepartment of Oncology, The Second Affiliated Hospital, Medical College of Zhejiang University, Hangzhou, 310009, China. zrsj@zju.edu.cn.
Zhejiang Chinese Medical University · CNSecond Affiliated Hospital of Zhejiang University · CNSutherland Hospital · AUZhejiang Provincial People's Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo investigate the potential efficacy of panaxadiol saponins component (PDS-C), a biologically active fraction isolated from total ginsenosides, to reverse chemotherapy-induced myelosuppression and pancytopenia caused by cyclophamide (CTX).

methodsMice with myelosuppression induced by CTX were treated with PDS-C at a low- (20 mg/kg), moderate- (40 mg/kg), or high-dose (80 mg/kg) for 7 consecutive days. The level of peripheral white blood cell (WBC), neutrophil (NEU) and platelet (PLT) were measured, the histopathology and colony formation were observed, the protein kinase and transcription factors in hematopoietic cells were determined by immunohistochemical staining and Western blot.

resultsIn response to PDS-C therapy, the peripheral WBC, NEU and PLT counts of CTX-induced myelosuppressed mice were significantly increased in a dose-dependent manner. Similarly, bone marrow histopathology examination showed reversal of CTX-induced myelosuppression with increase in overall bone marrow cellularity and the number of hematopoietic cells (P<0.01). PDS-C also promoted proliferation of granulocytic and megakaryocyte progenitor cells in CTX-treated mice, as evidenced by significantly increase in colony formation units-granulocytes/monocytes and -megakaryocytes (P<0.01). The enhancement of hematopoiesis by PDS-C appears to be mediated by an intracellular signaling pathway, this was evidenced by the up-regulation of phosphorylated mitogen-activated protein kinase (p-MEK) and extracellular signal-regulated kinases (p-ERK), and receptor tyrosine kinase (C-kit) and globin transcription factor 1 (GATA-1) in hematopoietic cells of CTX-treated mice (P<0.05).

conclusionsPDS-C possesses hematopoietic growth factor-like activities that promote proliferation and also possibly differentiation of hematopoietic progenitor cells in myelosuppressed mice, probably mediated by a mechanism involving MEK and ERK protein kinases, and C-kit and GATA-1 transcription factors. PDS-C may potentially be a novel treatment of myelosuppression and pancytopenia caused by chemotherapy.

Indexed as

AnimalsAntineoplastic AgentsCell ProliferationCyclophosphamideExtracellular Signal-Regulated MAP KinasesGATA1 Transcription FactorGinsenosidesHematopoiesisMiceMitogen-Activated Protein Kinase KinasesMyeloid CellsPanaxPancytopeniaPhosphorylationProto-Oncogene Proteins c-kitSaponinsAntineoplastic AgentsCyclophosphamideExtracellular Signal-Regulated MAP KinasesGATA1 Transcription FactorGinsenosidesMitogen-Activated Protein Kinase KinasespanaxadiolProto-Oncogene Proteins c-kitSaponinschemotherapy-induced myelosuppressionChinese medicineextracellular signal-regulated kinaseginsenosidesglobin transcription factor 1mitogen-activated protein kinasepanaxadiol saponins componentreceptor tyrosine kinase

Identifiers

PMID28432529
OpenAlexW2606631555

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.